The neuroimaging team

An image of 4 different aspects of the brain recorded through advanced neuroimaging techniques

Our team develops advanced neuroimaging tools to facilitate health professionals in diagnosing, monitoring and treating brain conditions.

Developing tools to unlock critical clinical information from brain images.

Our goal

Our team of scientists develop technologies to unlock crucial clinical information from brain images.

The tools could increase efficacy in clinical trials, allowing new therapies to be developed faster and at less cost.

Our science

Neurodegenerative diseases refer to a group of age-related brain illnesses that result in progressive loss of brain tissue and cognitive function.

Early detection is now recognized as the critical path to effective treatment for various forms of neurodegenerative diseases, including Alzheimer’s disease (AD). Early detection can enable interventions prior to widespread tissue loss.

The primary pathway for early detection is through identification of neuropathology biomarkers with neuro-imaging modalities.

With the help of clinicians, we apply our knowledge of medical instrumentation, image processing and machine learning algorithms to develop and improve disruptive technologies that extract clinically meaningful metrics (biomarkers).

Our projects develop cutting-edge validated methods to acquire and automatically extract information from medical images. to improve diagnosis, treatment delivery efficiency, cost-effectiveness and patient quality of life. 

Our collaborators

We collaborate with Austin Health, Florey Institute of Neuroscience, McCusker Alzheimer’s Research Foundation (MARF) Edith Cowan University (ECU), Macquarie University, AIBL, KARVIAH and PISA studies.  

Our impact

Our technologies offer a better understanding of neurodegenerative diseases.

We developed CapAIBL, and using the tool we identified a 15-17 year pre-clinical window for preventative treatment in AD. This resulted in the first preclinical trials.

Our software also improves the efficacy of clinical trials. We validated the first accurate blood biomarkers for AD, which is five time cheaper than a PET scan.

Finally, our technologies provide clinicians with large set of biomarkers and predictive models. Clinicians can offer more confident care to patients and develop personalised solutions to keep people healthy. 

Our solutions

To ensure that the Neuroimaging team remain at the forefront of the digital disruption and maintain our competitive advantage, we are investing resources in artificial intelligence technologies for automated quantification of imaging biomarkers.

We are ensuring that we can provide high-throughput and harmonised delivery of our science to promote the ever-increasing pull for data as we move towards to personalised health metrics.